According to the DIA, the biopharmaceutical industry in India will be worth $1 billion by 2010, up from $60 million in 2003 and $100 million in 2006. The DIA intends to capitalize on the industry’s rapid growth in the country and has also established a provisional Advisory Council of India to help plan its initiatives in the country.
Linda McGoldrick, DIA’s worldwide executive director, predicts that by 2011, India will account for 15% share in the global clinical trials market.